7 strategies for early-stage founders to build a predictable flow of high-value leads - partners, customers, and investors — without a full sales team.
You've built an incredible technology or service that you're sure biotech & pharma will love. Now comes the hard part - selling to scientists, arguably the most skeptical and scrutinizing of buyers.
Unlike SaaS or consumer tech, selling into biotech & pharma means sales cycles stretching from 9–24 months. Decision-makers are highly educated, specialized, and hard to reach (we already mentioned skeptical). That means your pitch needs to be backed up with scientific and personal credibility, with a window of opportunity dictated by shaped by funding timelines, IP clocks, and clinical milestones.
The teams who succeed at pipeline growth aren't the even the smartest or most charismatic networkers. Rather, they're the ones who treat lead generation like a science, like a system - continuously iterating and improving on what works, and discarding what doesn't.
This playbook is such a system.
Selling into biotech & pharma, the biggest mistake isn't just not doing enough outreach (outbound NEEDS to be part of your process) - it's also doing too much outreach to the wrong people at the wrong time.
You need to understand the rules of the game before we can jump into tactics. Selling into biotech & pharma isn't like selling into software or other vertical, meaning our pipeline strategy needs to be different.
In many industries, particularly SaaS, lead gen is a volume game - send out thousands (even tens of thousands) of emails across hundreds of domains and hope for the best. This doesn't work selling into biotech & pharma - first and foremost because trust plays a big part & the TAM (total addressable market) we're working with is much smaller.
Unsurprisingly, your prospective customers and partners - could be big pharma BD/competitive intel teams, CROs/CDMOs operations/engineering, senior research scientists etc. - are bombarded with pitches. These folks aren't going to book a meeting because of a clever subject line - you need to demonstrate scientific credibility, third-party validation, and a clear articulation of where your tech, product, or service fits in their pipeline or portfolio. Trust is the currency, and you'll need multiple touchpoint to build this, both virtually and in real life.
Biotech deals routinely involve 6–12+ stakeholders, spanning across scientists, business development, legal, finance, IT, and C-suite executives (all depending on what you're actually selling and to whom). Understanding who holds veto power, who champions internally, and who controls timing is more valuable than any contact database. Multi-threading (proactively being in-touch with all decision making parties) is crucial.
When selling into biotech & pharma, much like with other enterprise scale sales, you need to navigate a complex decision ecosystem to make the deal happen. Map it before you approach it - your deal champion (whoever you're taking to that really wants your product/service) will be key for this.
We'd argue this is the most crucial thing about selling into biotech & pharma - since we're not dealing with a massive TAM, remember that a prospect who isn't ready today will, eventually (assuming the company doesn't go belly-up) be ready to buy later. Always set touch-points out every 6-12 months (depending on your product/service), and have a nurture strategy built out that involves sending prospects (with permission) information that they might find useful for their work (not just more ads for your product/service). This provides an excuse to stay in-touch and add value - meaning you'll be top-of-mind when they finally enter the buying window.
The ICP (Ideal Customer Profile) is the strategic foundation of all effective lead gen in biotech & pharma. Getting this right makes every downstream activity more precise and more efficient.
You cannot build a pipeline without first defining what fills it, and experimenting to actually understand if that definition holds water. Too many companies find an ok-enough ICP and go full-out, burning prospects and their resources in the process. The more time you spend here really figuring out your ICP, the better your results will be.
Does the company's workflow, pipeline stage, or research focus create a natural need for your product or service? Are they in a therapeutic area, modality, or development phase where your solution solves a real bottleneck?
Are they scaling a function your product supports — hiring, building out infrastructure, or entering a new phase of development? Have they recently raised funding, announced a new program, or hit a milestone that triggers buying activity?
Do they have budget allocated for tools or services like yours? Are they venture-backed with fresh capital, or a mid-size pharma with predictable procurement cycles? Have they purchased comparable solutions in the last 12–24 months?
How reachable are the decision-makers? Are the right people identifiable on LinkedIn, active at conferences, or publishing in your space? Can you build relevance through insights, content, or timely outreach tied to their priorities — or is the buying committee buried behind procurement and gatekeepers?
Your ICP framework gives you four dimensions to score against. The tier a prospect lands in depends on how many quadrants they light up — and how strongly.
For each potential target company, run through the four quadrants mentioned above and assign a simple High / Medium / Low signal. Rephrased below with an execution focus:
Pull their pipeline, platform, or published research focus. Do they operate in the therapeutic areas, development stages, or workflows where your product or service delivers clear value? Eg. for a CDMO selling manufacturing services, the company's current or rapidly approaching clinical stage matters.
Look for recent signals: new funding rounds, leadership hires in relevant functions, program advancements, facility expansions, or public statements about strategic priorities. A company that just raised a Series B and is hiring a Head of CMC/MSAT is in a fundamentally different buying posture than one in stealth mode.
Check funding stage, last raise amount, and deal history. A pre-seed company with $2M in the bank probably isn't buying your enterprise platform. A mid-cap pharma that just acquired a pipeline asset and has a track record of outsourcing - much more interesting.
How reachable are the decision-makers? Can you identify the right person by name and title? Are they active on LinkedIn, speaking at conferences, or engaging with content in your space? Or is the org a black box where every email goes to info@?
The fit is obvious, the timing is right, they can afford you, and you can reach the right person. These get deep personalization - custom research, tailored messaging, multi-channel sequences, and real strategic thought behind every touch. For your outbound here, highly recommend a human-person is reviewing and approaching all touch-points.
The fit is there but maybe the timing isn't perfect, or you can't identify the exact buyer yet. These get systematic, well-crafted outreach - personalized enough to be relevant, templated enough to scale. Spot-checking messaging by a human is recommended, but doesn't require the same amount of effort as a Tier 1 prospect. Many Tier 2 prospects become Tier 1 when a trigger event hits.
Usually strong on Scientific Fit alone. These are your watch list or, if capacity allows, light-touch list - send a LinkedIn connection request or a single email to get on their radar, but ideally you're monitoring for a trigger event that moves them up in priority before setting off on extensive outreach: a funding announcement, a key hire, a program milestone etc.
Trigger events are what move companies between tiers. When one fires on a Tier 2 or Tier 3 prospect, move fast - you now have a reason to reach out that's timely, relevant, and impossible to fake.
New funding rounds (Series A+ for biotechs, new budget cycles for pharma) · Leadership hires in your buyer's function · Pipeline advancements like IND filings or phase transitions · Facility expansions or technology platform changes · M&A activity, in-licensing deals, or failed programs that create gaps · Regulatory milestones or patent expirations that shift strategic priorities
Set up monitoring through funding databases, LinkedIn alerts (eg. set-up job alerts), SEC filings, press releases, and industry news (eg. google alerts) - Clay is also great for this. The companies on your Tier 3 list today can be your closed-won deal 12 months from now - if you're monitoring for and act on the right signal.
Not all channels are equal in impact or effort. These seven strategies have the highest ROI when you're selling into biotech & pharma, in no particular order.
Publishing in high-impact journals is a powerful (ableit high effort) way of establishing credibility with your target scientific audience. Makes for a great inbound lead-gen asset that you can segment out into additional pieces for social media, and something to reference in our outreach to further establish credibility.
Don't let the $$$ you've put towards conferences go to waste with just a few "Excited to announce I'll be attending..." posts on LinkedIn the week before the event. Pre-schedule your 1:1 meetings via outbound to your network, ideally 3 weeks in advance. Even better if the conference has an internal partnering app where you can book meetings. Come prepared with a short slide deck on your product/service that you can whip out on an iPad or laptop, and have concrete follow-up steps ready to go after the event ends.
In terms of events to attend, the heavy hitters like JPM, BIO International, Interphex, and various global CPHI events can be on your list depending on focus, but also don't neglect smaller, niche events or local events (helps to be near a biotech hub like San Francisco, San Diego, Boston, London etc.)
Your scientific advisors, board members, and early investors are sitting on undiscovered relationship assets. Map their networks systematically on LinkedIn, and ask them to make introductions to people at organizations that fit your ICP. A single warm introduction from a trusted individual carries more weight than 50 cold emails. Build a structured process for requesting and following up on introductions (TeamLink in Sales Nav is great for this if these people are associated with your org on LinkedIn).
People buy from people, and that applies to biotech & pharma as well. Humanizing your team, especially your senior leaders, by getting their opinions and thoughts out there through channels like LinkedIn, a podcasts, or webinar appearances can position your company as a category expert. This all helps drive inbound leads, which can have a much higher chance of converting since these prospects are likely in the buying cycle. Focus content on the problems your ICP faces, and how your product/service can alleviate these issues.
Getting into a prospect's radar is only step one. Staying top of mind - without being annoying - is where the deal gold is.
The biotech and pharma sales cycles can take anywhere from 9 - 24 months from first contact to signed deal, so your follow-up and nurture strategy needs to be built for constant, but occasional, value-add check-ins.
Ideally, (almost) every touchpoint in your nurture sequence should deliver something useful to the prospect - a relevant paper or news article, an invitation to a webinar or to download a whitepaper. You can do the occasional check-ins that are just "hey, better time now to connect?" but keep these to a minimum, and only after appreciable time (eg. a quarter) has passed.
Without a structured CRM, your pipeline is just a collection of conversations with no system connecting them. Track every interaction, note every preference expressed, flag every trigger event. With the advent of AI (Claude Code, Clay, etc.) a lot of these trigger events/signals can be automated to update your CRM, surfacing high priority leads for your team to reach out to. But even then, don't get overwhelmed - even a well-configured spreadsheet beats a disorganized enterprise CRM tool.
Nurture sequences can become indefinite delays disguised as relationship-building. Set explicit advancement criteria (from those aforementioned signals & triggers) and an expiry date for when it's time to pause. Eg. if a signal came in, but you weren't able to establish contact/move the deal forward within a couple of months, might be time to move them to a lower-priority tier.
Treat pipeline growth like you would a scientific experiment - what is measured is ultimately managed (and optimized). Below are the metrics you should care about, and the vanity metrics you should stop tracking.
You don't need a complex analytics stack. You need five numbers, tracked consistently, with honest reviews every quarter.
Just straight meetings booked is a vanity metric - what you really need to figure out is how many qualified conversations you're having with decision-makers or champions who fit your ICP.
What % of first meetings convert to proposal? What % of proposals convert to a 2nd meeting (and how long does this take)? Track not only the percentage of transition but also the speed. A low and slow rate at any one stage reveals exactly where your process is breaking.
Track exactly which channel each lead is originating from, across both outbound and inbound. Which channels produce your highest-converting leads? Allocate time and resources towards these channels.
How long from first outreach to first qualified meeting? This measures the effectiveness of your targeting and messaging. If it's over 45 days consistently, your entry point, hooks, or overall approach needs reworking.
Stop counting LinkedIn impressions and email open rates. Count conversations that move toward deals.
Science 2 Sales works exclusively with companies selling into biotech, life sciences, and pharma to build systematic, scalable lead generation engines that get you in-touch with your target prospects at the right time.
Book a Strategy Call →